Silverfin false false 29/02/2024 01/03/2023 29/02/2024 R D Fryer 04/02/2022 K Skripka 04/02/2022 06 September 2024 no description of principal activity 13894822 2024-02-29 13894822 bus:Director1 2024-02-29 13894822 bus:Director2 2024-02-29 13894822 2023-02-28 13894822 core:CurrentFinancialInstruments 2024-02-29 13894822 core:CurrentFinancialInstruments 2023-02-28 13894822 core:ShareCapital 2024-02-29 13894822 core:ShareCapital 2023-02-28 13894822 core:RetainedEarningsAccumulatedLosses 2024-02-29 13894822 core:RetainedEarningsAccumulatedLosses 2023-02-28 13894822 2023-03-01 2024-02-29 13894822 bus:FilletedAccounts 2023-03-01 2024-02-29 13894822 bus:SmallEntities 2023-03-01 2024-02-29 13894822 bus:AuditExemptWithAccountantsReport 2023-03-01 2024-02-29 13894822 bus:PrivateLimitedCompanyLtd 2023-03-01 2024-02-29 13894822 bus:Director1 2023-03-01 2024-02-29 13894822 bus:Director2 2023-03-01 2024-02-29 13894822 2022-03-01 2023-02-28 iso4217:GBP xbrli:pure

Company No: 13894822 (England and Wales)

DERMAL SCIENCE LTD

Unaudited Financial Statements
For the financial year ended 29 February 2024
Pages for filing with the registrar

DERMAL SCIENCE LTD

Unaudited Financial Statements

For the financial year ended 29 February 2024

Contents

DERMAL SCIENCE LTD

COMPANY INFORMATION

For the financial year ended 29 February 2024
DERMAL SCIENCE LTD

COMPANY INFORMATION (continued)

For the financial year ended 29 February 2024
DIRECTORS R D Fryer
K Skripka
REGISTERED OFFICE Cooper Buildings
Arundel Street
Sheffield
S1 2NS
United Kingdom
COMPANY NUMBER 13894822 (England and Wales)
ACCOUNTANT Gravita Business Services Limited
Aldgate Tower
2 Leman Street
London
E1 8FA
United Kingdom
DERMAL SCIENCE LTD

BALANCE SHEET

As at 29 February 2024
DERMAL SCIENCE LTD

BALANCE SHEET (continued)

As at 29 February 2024
Note 2024 2023
£ £
Current assets
Stocks 3 13,970 98,531
Debtors 4 113,940 30,913
Cash at bank and in hand 758,455 443,799
886,365 573,243
Creditors: amounts falling due within one year 5 ( 358,354) ( 321,254)
Net current assets 528,011 251,989
Total assets less current liabilities 528,011 251,989
Net assets 528,011 251,989
Capital and reserves
Called-up share capital 10 10
Profit and loss account 528,001 251,979
Total shareholder's funds 528,011 251,989

For the financial year ending 29 February 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Dermal Science Ltd (registered number: 13894822) were approved and authorised for issue by the Board of Directors on 06 September 2024. They were signed on its behalf by:

K Skripka
Director
DERMAL SCIENCE LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 29 February 2024
DERMAL SCIENCE LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 29 February 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Dermal Science Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Cooper Buildings, Arundel Street, Sheffield, S1 2NS, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Profit and Loss Account as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss.

If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Financial assets
An asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

For financial assets carried at amortised cost, the amount of impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial assets are derecognised when and only when the contractual rights to the cash flows from the financial asset expire or are settled, or the Company transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or the Company, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Stocks

2024 2023
£ £
Stocks 13,970 87,830
Raw materials 0 10,701
13,970 98,531

4. Debtors

2024 2023
£ £
Trade debtors 113,078 0
Other debtors 862 30,913
113,940 30,913

5. Creditors: amounts falling due within one year

2024 2023
£ £
Trade creditors 187,779 39,330
Amounts owed to Group undertakings 1,087 134,097
Taxation and social security 161,313 81,907
Other creditors 8,175 65,920
358,354 321,254

6. Related party transactions

No remuneration was paid to the directors during the period. The directors are the only key management personnel of the Company.

The Company has taken advantage of the exemption available under FRS 102 Section 1A not to disclose details of transactions with wholly owned members of the group headed by its parent company.

7. Ultimate controlling party

Parent Company:

Malaberg Ltd
Unit 206 Cooper Buildings, Arundel Street, Sheffield, South Yorkshire, England, S1 2NS